Yéssica Plata-Fernández

Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.

E. Alba, N. Ribelles, Víctor Navarro-Pérez, 2015, Clinical breast cancer.

Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients

E. Alba, C. Ramírez-Tortosa, P. Sánchez‐Rovira, 2014, Clinical and Translational Oncology.

Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes

J. M. Jerez, E. Alba, C. Ramírez-Tortosa, 2018, Modern Pathology.

The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.

C. Ramírez-Tortosa, P. Sánchez‐Rovira, Víctor Navarro-Pérez, 2013, Clinical breast cancer.